Literature DB >> 6193136

The sensitivity of isolated osteoclasts to morphological transformation by calcitonin.

T J Chambers, A Moore.   

Abstract

We recently developed a technique for isolating osteoclasts from other bone cells which allows the direct effect of hormones on these cells to be assessed. We found that calcitonin (CT), which inhibits osteoclastic bone resorption, abolished cytoplasmic movement in these cells. In this paper we use the shape-change which accompanies immotility to define the sensitivity of osteoclasts to human and salmon CT. Concentrations of human CT above 62 pg/ml and salmon CT above 3 pg/ml regularly induced the shape-change in osteoclasts which corresponds to complete inhibition of cytoplasmic motility. Morphological transformation of osteoclasts by such low concentrations implies that CT may inhibit bone resorption by inhibiting the motility of the bone-resorptive cell. Even relatively high concentrations of other hormones had no effect on the sensitivity of osteoclasts to CT. This suggests that the response of isolated osteoclasts to CT is sufficiently specific and sensitive to be used as a bioassay, and we used the response to compare the biological potency of several samples of known immunoassayable CT content.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6193136     DOI: 10.1210/jcem-57-4-819

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  37 in total

Review 1.  Calcitonin and calcitonin receptors: bone and beyond.

Authors:  M Pondel
Journal:  Int J Exp Pathol       Date:  2000-12       Impact factor: 1.925

Review 2.  Nasal calcitonin.

Authors:  S L Silverman
Journal:  Endocrine       Date:  1997-04       Impact factor: 3.633

3.  A study of the antiresorptive activity of salmon calcitonin microspheres using cultured osteoclastic cells.

Authors:  Bhas A Dani; Adrian T Raiche; David A Puleo; Patrick P DeLuca
Journal:  AAPS PharmSciTech       Date:  2002       Impact factor: 3.246

Review 4.  Intranasal salcatonin (salmon calcitonin). A review of its pharmacological properties and role in the management of postmenopausal osteoporosis.

Authors:  G L Plosker; D McTavish
Journal:  Drugs Aging       Date:  1996-05       Impact factor: 3.923

5.  Serum bone Gla protein in streak gonad syndrome.

Authors:  J Zséli; P Bösze; P Lakatos; P Vargha; G Tarján; E Kollin; C Horváth; J László; I Holló
Journal:  Calcif Tissue Int       Date:  1991-06       Impact factor: 4.333

6.  Influence of food intake on the bioavailability and efficacy of oral calcitonin.

Authors:  Morten A Karsdal; Inger Byrjalsen; Möise Azria; Michel Arnold; Les Choi; Bente J Riis; Claus Christiansen
Journal:  Br J Clin Pharmacol       Date:  2009-04       Impact factor: 4.335

Review 7.  The molecular mechanism behind bone remodelling: a review.

Authors:  Peter Proff; Piero Römer
Journal:  Clin Oral Investig       Date:  2009-03-25       Impact factor: 3.573

Review 8.  Salmon calcitonin: a review of current and future therapeutic indications.

Authors:  C H Chesnut; M Azria; S Silverman; M Engelhardt; M Olson; L Mindeholm
Journal:  Osteoporos Int       Date:  2007-12-11       Impact factor: 4.507

Review 9.  The pathobiology of the osteoclast.

Authors:  T J Chambers
Journal:  J Clin Pathol       Date:  1985-03       Impact factor: 3.411

Review 10.  Peptides from the calcitonin genes: molecular genetics, structure and function.

Authors:  L H Breimer; I MacIntyre; M Zaidi
Journal:  Biochem J       Date:  1988-10-15       Impact factor: 3.857

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.